Variations in Use of Second-Generation Antipsychotic Medication by Race Among Adult Psychiatric Patients

Variations in Use of Second-Generation Antipsychotic Medication by Race Among Adult Psychiatric Patients

OBJECTIVE: This study examined variations in the use of second-generation antipsychotic medication among African-American and non-Hispanic white patients in a national sample of adults who were treated by psychiatrists. METHODS: This study used data from studies of psychiatric patients and treatment...

Full description

Saved in:
Bibliographic Details
Published in:Psychiatric services (Washington, D.C.) Vol. 55; no. 6; pp. 677 - 684
Main Authors: Herbeck, Diane M, West, Joyce C, Ruditis, Ilze, Duffy, Farifteh F, Fitek, Diana J, Bell, Carl C, Snowden, Lonnie R
Format: Journal Article
Language:English
Published: Washington, DC American Psychiatric Publishing 01-06-2004
American Psychiatric Association
Subjects:
Adult
African Americans - psychology
African Americans - statistics & numerical data
Aged
Antipsychotic Agents - therapeutic use
Biological and medical sciences
Drug Utilization
European Continental Ancestry Group - psychology
European Continental Ancestry Group - statistics & numerical data
Female
Humans
Insurance, Pharmaceutical Services
Male
Medical sciences
Mental Disorders - drug therapy
Mental Disorders - ethnology
Middle Aged
Multivariate Analysis
Neuropharmacology
Pharmacology. Drug treatments
Practice Patterns, Physicians
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Residence Characteristics
Schizophrenia - drug therapy
Socioeconomic Factors
United States
United States
North America
America
Human
Consumption
Drug
Neuroleptic
Use
Mental health
Variations
Chemotherapy
Race
Mental disorder
Adult
Antipsychotic
Public health
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVE: This study examined variations in the use of second-generation antipsychotic medication among African-American and non-Hispanic white patients in a national sample of adults who were treated by psychiatrists. METHODS: This study used data from studies of psychiatric patients and treatments that were conducted by the American Psychiatric Institute for Research and Education's (APIRE's) Practice Research Network (PRN). Psychiatrists provided detailed clinical data for 126 African-American patients and 574 white patients who were randomly selected and for whom antipsychotic medications were prescribed. The study assessed differences by race in the use of second-generation antipsychotic medication, adjusting for clinical, sociodemographic, and health-system characteristics, including patients' source of payment for treatment. RESULTS: African-American patients were less likely than white patients to receive second-generation antipsychotic medications (49 percent compared with 66 percent). After the analysis statistically adjusted for clinical, sociodemographic, and health-system characteristics, African-American patients remained less likely than white patients to receive second-generation antipsychotics. CONCLUSIONS: Because African Americans tended to receive medications that are not first-line recommended treatments and that have a greater risk of producing tardive dyskinesia and extrapyramidal side effects, African Americans could be expected to suffer diminished clinical status. This disparity may also contribute to lower rates of adherence and to more frequent emergency department visits and psychiatric hospitalizations among African Americans
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1075-2730
1557-9700
DOI:10.1176/appi.ps.55.6.677